Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    100.0%

    Based on 2 completed trials

    Completion Rate
    100%(2/2)
    Active Trials
    0(0%)
    Results Posted
    0%(0 trials)

    Phase Distribution

    Phase 4
    1
    33%

    Phase Distribution

    0

    Early Stage

    0

    Mid Stage

    1

    Late Stage

    Phase Distribution1 total trials
    Phase 4Post-market surveillance
    1(100.0%)

    Highest Phase Reached

    Phase 4

    Trial Status & Enrollment

    Completion Rate

    66.7%

    2 of 3 finished

    Non-Completion Rate

    33.3%

    1 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    3

    all time

    Status Distribution
    Completed(2)
    Terminated(1)

    Detailed Status

    Completed2
    Withdrawn1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    3
    Active
    0
    Success Rate
    100.0%
    Most Advanced
    Phase 4

    Trials by Phase

    Phase 41 (100.0%)

    Trials by Status

    withdrawn133%
    completed267%

    Recent Activity

    0 active trials
    Showing 3 of 3
    completed

    Prognostic Markers of Inflammation in Infants Undergoing Cardiopulmonary Bypass

    NCT03143348
    completed

    Endothelial Microparticles: A Novel Marker of Vascular Dysfunction

    NCT02230202
    withdrawnphase_4

    Study Evaluating Inhibitor Specificity in Hemophilia A

    NCT00151385

    Clinical Trials (3)

    Showing 3 of 3 trials
    NCT03143348

    Prognostic Markers of Inflammation in Infants Undergoing Cardiopulmonary Bypass

    Completed
    NCT02230202

    Endothelial Microparticles: A Novel Marker of Vascular Dysfunction

    Completed
    NCT00151385Phase 4

    Study Evaluating Inhibitor Specificity in Hemophilia A

    Withdrawn

    All 3 trials loaded

    Drug Details

    Intervention Type
    Varies by study
    Total Trials
    3